• 1
    AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J. Urol. 2003; 170: 53047.
  • 2
    Docherty JR. Subtypes of functional alpha1- and alpha2-adrenoceptors. Eur. J. Pharmacol. 1998; 361: 115.
  • 3
    Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ, Minneman KP, Ruffolo RR Jr. International union of pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol. Rev. 1995; 47:26770.
  • 4
    Hawrylyshyn KA, Michelotti GA, Coge F, Guenin SP, Schwinn DA. Update on human alpha1-adrenoceptor subtype signaling and genomic organization. Trends Pharmacol. Sci. 2004; 25: 44955.
  • 5
    Richardson CD, Donatucci CF, Page SO, Wilson KH, Schwinn DA. Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes. Prostate 1997; 33: 559.
  • 6
    Schwinn DA, Johnston GI, Page SO et al. Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J. Pharmacol. Exp. Ther. 1995; 272: 13442.
  • 7
    Price DT, Lefkowitz RJ, Caron MG, Berkowitz D, Schwinn DA. Localization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues: implications for human alpha-adrenergic physiology. Mol. Pharmacol. 1994; 45: 1715.
  • 8
    Andersson KE, Lepor H, Wyllie MG. Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate 1997; 30: 20215.
  • 9
    Kojima Y, Sasaki S, Shinoura H et al. Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients. Prostate 2007; 67: 128592.
  • 10
    Smith M, Schambra U, Wilson K, Page S, Schwinn D. Alpha1-adrenergic receptors in human spinal cored: specific localized expression of mRNA encoding alpha1-adrenergic receptor subtypes at four distinct levels. Mol. Brain Res. 1999; 63: 25461.
  • 11
    Malloy BJ, Price DT, Price RR et al. Alpha1-adrenergic receptor subtypes in human detrusor. J. Urol. 1998; 160: 93743.
  • 12
    Blue DR Jr, Grino P, Jung DT, Harbison MP, Ford APDW. Evaluation of Ro 70-0004, a selective α1a-adrenoceptor antagonist, in men with benign prostatic hyperplasia (BPH) [abstract]. Proceedings of the Fifth International Consultation on BPH 2000: 550.
  • 13
    Bouchelouche K, Andersen L, Alvarez S, Nordling J, Bouchelouche P. Increased contractile response to phenylephrine in detrusor of patients with bladder outlet obstruction: effect of the alpha1A and alpha1D-adrenergic receptor antagonist tamsulosin. J. Urol. 2005; 173: 65761.
  • 14
    Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. Br. J. Urol. 2006; 97: 74751.
  • 15
    Takahashi S, Tajima A, Matsushima H, Kawamura T, Tominage T, Kitamura T. Clinical efficacy of an alpha1A/d-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. Int. J. Urol. 2006; 13: 1520.
  • 16
    Ishizuka O, Persson K, Mattiasson A, Naylor A, Wyllie M, Andersson K. Micturition in conscious rats with and without bladder outlet obstruction: role of spinal alpha 1-adrenoceptors. Br. J. Pharmacol. 1996; 117: 9626.
  • 17
    Ohtake A, Ukai M, Saitoh C et al. Effect of tamsulosin on spontaneous bladder contraction in conscious rats with bladder outlet obstruction: comparison with effect on intraurethral pressure. Eur. J. Pharmacol. 2006; 545: 18591.
  • 18
    Nomiya M, Yamaguchi O. Functional and anatomical effects of hormonally induced experimental prostate growth: a urodynamic model of benign prostatic hyperplasia (BPH) in the beagle. Prostate 2003; 58: 15663.
  • 19
    Ishihama H, Momota Y, Yanase H, Wang X, de Groat W, Kawatani M. Activation of alpha1D adrenergic receptors in the rat urothelium facilitates the micturition reflex. J. Urol. 2006; 175: 35864.
  • 20
    Yokoyama O, Yusup A, Oyama N, Aoki Y, Miwa Y, Akino H. Improvement in bladder storage function by tamsulosin depends on suppression of C-fiber urethral afferent activity in rats. J. Urol. 2007; 177: 7715.
  • 21
    Rudner X, Berkowitz D, Booth J et al. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation 1999; 100: 233643.
  • 22
    de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur. Urol. 1998; 33: 4818.
  • 23
    Souverein PC, Van Staa TP, Egberts AC, De la Rosette JJ, Cooper C, Leufkens HG. Use of alpha-blockers and the risk of hip/femur fractures. J. Intern. Med. 2003; 254: 54854.
  • 24
    Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Origasa H, Group TUCT. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. Br. J. Urol. 2005; 96: 5816.
  • 25
    de Mey C. Cardiovascular effects of alpha-blockers for the treatment of symptomatic BPH. Eur. Urol. 1998; 34 Suppl. 2: 1828;discussion 47.
  • 26
    Nickel JC. The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia. Urology 2003; 62: 3441.
  • 27
    Harada K, Ohmori M, Kitoh Y, Sugimoto K, Fujimura A. A comparison of the antagonistic activities of tamsulosin and terazosin against human vascular alpha1-adrenoceptors. Jpn. J. Pharmacol. 1999; 80: 20915.
  • 28
    Masumori N, Hashimoto J, Itoh N, Tsukamoto T, Group TS. Short-term efficacy and long-term compliance/treatment failure of the alpha-1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Scand. J. Urol. Nephrol. 2007; 41:4229.
  • 29
    Ikemoto K, Kiyota H, Ohishi Y et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study. Int. J. Urol. 2003; 10: 58794.
  • 30
    Wilde MI, Fitton A, Sorkin EM. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs Aging 1993; 3: 25877.
  • 31
    Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295320.
  • 32
    Wilde MI, Fitton A, McTavish D. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs 1993; 45: 41029.
  • 33
    Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998; 51: 892900.
  • 34
    Hisasue S, Furuya R, Itoh N, Kobayashi K, Furuya S, Tsukamoto T. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int. J. Urol. 2006; 13: 131116.
  • 35
    Hellstrom WJ & Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol 2006; 176: 15291533.
  • 36
    Chobanian AV, Bakris GL, Black HR et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 120652.
  • 37
    Albertsen PC, Pellissier JM, Lowe FC, Girman CJ, Roehrborn CG. Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study. Clin. Ther. 1999; 21: 100624.
  • 38
    McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N. Engl. J. Med. 1998; 338: 55763.
  • 39
    McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 2003; 349: 238798.
  • 40
    Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 43441.
  • 41
    Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 280: 16049.
  • 42
    Wilt T, Ishani A, MacDonald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst. Rev. 2002: CD001044.
  • 43
    Yamanishi T, Yasuda K, Kamai T et al. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. Int. J. Urol. 2004; 11: 5019.
  • 44
    Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int. 2006; 97: 10036.
  • 45
    Brawer MK, Lin DW, Williford WO, Jones K, Lepor H. Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359. Prostate 1999; 39: 2349.
  • 46
    McConnell JD. MSC: the long term effects of medical therapy on the progression of BPH: results from the MTOPS trial. J. Urol. 2002; 167: 1042.
  • 47
    Kirby RS, Roehrborn C, Boyle P et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 11926.
  • 48
    McAuley IW, Kim NN, Min K, Goldstein I, Traish AM. Intracavernosal sildenafil facilitates penile erection independent of the nitric oxide pathway. J. Androl. 2001; 22: 6238.
  • 49
    O'Leary MP. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications. Urology 2003; 62: 1523.
  • 50
    Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur. Urol. 2003; 44: 63749.
  • 51
    Palea S, Barras M. Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum. BJU Int. 2003; 91: 8737.
  • 52
    Mizusawa H, Hedlund P, Sjunnesson J, Brioni JD, Sullivan JP, Andersson KE. Enhancement of apomorphine-induced penile erection in the rat by a selective alpha(1D)-adrenoceptor antagonist. Br. J. Pharmacol. 2002; 136: 7018.
  • 53
    Kloner RA. Sex and the patient with cardiovascular risk factors: focus on sildenafil. Am. J. Med. 2000; 109 (Suppl. 9A): 13S21S; discussion 29S–30S.
  • 54
    Webb DJ, Muirhead GJ, Wulff M, Sutton JA, Levi R, Dinsmore WW. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J. Am. Coll. Cardiol. 2000; 36: 2531.
  • 55
    Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002; 90: 8369.
  • 56
    McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J. Urol. 2007; 177: 10717.
  • 57
    McVary KT, Roehrborn CG, Kaminetsky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Urol. 2007; 177: 14017.
  • 58
    Schwinn D. Alpha(1)-adrenergic receptor antagonists and the iris: new mechanistic insights into floppy iris syndrome. Surv Ophthalmol. 2006; 51: 50112.
  • 59
    Michel M, Okutsu H, Noguchi Y et al. In vivo studies on the effects of alpha1-adrenoceptor antagonists on pupil diameter and urethral tone in rabbits. Naunyn Schmiedebergs Arch. Pharmacol. 2006; 372: 34653.